<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multifocal motor neuropathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multifocal motor neuropathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multifocal motor neuropathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dale J Lange, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jessica Robinson-Papp, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H126380735">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multifocal motor neuropathy (MMN), also known as multifocal motor neuropathy with conduction block, is a rare neuropathy characterized by progressive, asymmetric weakness and atrophy without sensory abnormalities, a presentation similar to that of motor neuron disease. This review will discuss the clinical aspects of MMN. Other immune-mediated neuropathies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14174.html" rel="external">
          "Immune-mediated neuropathies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H197848989">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMN is considered an immune-mediated disorder given the following observations [
         <a href="#rid1">
          1-3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical improvement with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of anti-GM1 antibodies in many but not all patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A perivascular lymphocytic infiltration observed on nerve biopsy in some reports
        </p>
        <p>
        </p>
        <p>
         However, it is unclear whether anti-GM1 antibodies are involved in the pathogenesis of MMN or are merely an epiphenomenon of the disease [
         <a href="#rid3">
          3,4
         </a>
         ]. Elevated titers of anti-GM1 antibodies may be seen in 30 to 80 percent of patients [
         <a href="#rid2">
          2,5-7
         </a>
         ]. There are several reports of patients developing MMN after treatment with anti-tumor necrosis factor-alpha (anti-TNF-alpha) antibodies (eg,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">
          ixekizumab
         </a>
         ) [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Although MMN is associated with conduction block on electrodiagnostic studies, segmental nerve demyelination is not a consistent feature of MMN, and some degree of axonal loss is often present [
         <a href="#rid3">
          3
         </a>
         ]. One hypothesis is that the conduction block may be caused by an antibody-mediated attack affecting sodium channels and other nerve components at the nodes of Ranvier [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H126381447">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMN is a rare condition. The estimated prevalence of MMN is 0.6 to 2 per 100,000 population [
         <a href="#rid4">
          4,12
         </a>
         ]. Males are affected more frequently than females, with a ratio of 2.7:1 [
         <a href="#rid12">
          12
         </a>
         ]. Disease onset usually occurs between ages 20 to 50 years, with a mean onset ranging from age 30 to 40 years [
         <a href="#rid4">
          4
         </a>
         ]. Although rare, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG)-responsive MMN has been described in children as well [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H126379997">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The typical clinical presentation of MMN is one of subacute onset with asymmetric weakness [
         <a href="#rid1">
          1
         </a>
         ]. Lower motor neuron signs often present in a bibrachial pattern, producing arm and hand weakness without associated sensory loss [
         <a href="#rid5">
          5,14
         </a>
         ]. The weakness usually begins as a focal mononeuropathy affecting the distal arms; wrist drop and hand weakness are common initial symptoms [
         <a href="#rid15">
          15
         </a>
         ]. However, MMN can also present in the legs.
        </p>
        <p>
         The neuronal involvement in MMN is typically patchy, with some nerves unaffected and others severely involved. In one series of 88 patients, onset of muscle weakness involving the distal arm or distal leg was noted in 61 and 34 percent of patients, respectively [
         <a href="#rid12">
          12
         </a>
         ]. In patients with arm onset, progression usually involves spread of the weakness to the contralateral arm followed by the legs [
         <a href="#rid1">
          1
         </a>
         ]. Some patients develop fasciculations or cramps. Muscle atrophy occurs late in the course of the disease. Deep tendon reflexes are variably affected, being decreased in most cases but normal or brisk (but not pathologic) in others [
         <a href="#rid12">
          12
         </a>
         ]. Cranial nerves, bulbar muscles, and respiratory muscles are most often spared in MMN.
        </p>
        <p>
         Motor nerve conduction studies often show evidence of conduction block, representing focal demyelination. Sensory conduction through the same segment of nerve is normal. (See
         <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">
          "Overview of nerve conduction studies", section on 'Conduction block'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126380003">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of MMN is suspected on the basis of a compatible clinical presentation with progressive, usually asymmetric weakness without sensory abnormalities, upper motor neuron signs, or bulbar involvement. The diagnosis is supported by nerve conduction studies that demonstrate focal demyelination and conduction block (see
         <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">
          "Overview of nerve conduction studies", section on 'Conduction block'
         </a>
         ) in motor nerves and normal sensory nerves [
         <a href="#rid1">
          1
         </a>
         ]. However, some patients have a similar clinical disorder but lack conduction block on nerve conduction studies, and this has been termed multifocal motor neuropathy without conduction block (MMNWOCB) [
         <a href="#rid14">
          14,16-18
         </a>
         ]. Other findings that support the diagnosis include finding abnormal A waves on electrodiagnostic studies [
         <a href="#rid19">
          19
         </a>
         ], axonal sprouting in motor nerve biopsies [
         <a href="#rid20">
          20
         </a>
         ], and abnormal hyperintense T2 signal and fascicular enlargement in affected nerves on magnetic resonance imaging (MRI) neurography [
         <a href="#rid21">
          21,22
         </a>
         ]. In these patients who lack conduction block, responsiveness to treatment with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is another supportive feature for the diagnosis of MMN [
         <a href="#rid3">
          3,14,23
         </a>
         ].
        </p>
        <p>
         Of note, conduction block can be missed on routine nerve conduction studies, particularly if demyelination is proximal or patchy [
         <a href="#rid1">
          1
         </a>
         ]. Therefore, an extensive survey of multiple nerves in upper and lower limbs should be performed using proximal stimulation (Erb's point) and late responses (F waves and H reflex) to assess proximal nerve segments. (See
         <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">
          "Overview of nerve conduction studies", section on 'Late responses'
         </a>
         .)
        </p>
        <p>
         Cerebrospinal fluid is acellular, and protein is typically normal.
        </p>
        <p class="headingAnchor" id="H197850503">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic criteria for MMN have been proposed by the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         The two core criteria for MMN (both must be present) are [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slowly progressive or stepwise progressive, focal, asymmetric limb weakness; that is, motor involvement in the motor nerve distribution of at least two nerves, for more than one month. If symptoms and signs are present only in the distribution of one nerve, only a possible diagnosis can be made.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No objective sensory abnormalities except for minor vibration sense abnormalities in the lower limbs.
        </p>
        <p>
        </p>
        <p>
         Supportive clinical criteria are as follows [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predominant upper limb involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased or absent tendon reflexes in the affected limb
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of cranial nerve involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cramps and fasciculations in the affected limb
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Response in terms of disability or muscle strength to immunomodulatory treatment
        </p>
        <p>
        </p>
        <p>
         Exclusion criteria are the following [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Upper motor neuron signs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Marked bulbar involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensory impairment more marked than minor vibration loss in the lower limbs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse symmetric weakness during the initial weeks
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H126381453">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of MMN primarily involves conditions that cause progressive limb weakness and atrophy without sensory loss and without upper motor neuron or bulbar manifestations [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         The main consideration in the differential diagnosis is amyotrophic lateral sclerosis/motor neuron disease. (See
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5138.html" rel="external">
          "Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"
         </a>
         .)
        </p>
        <p>
         In addition, the differential includes the lower motor neuron variants of amyotrophic lateral sclerosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive muscular atrophy (see
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Progressive muscular atrophy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flail arm syndrome (see
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Flail arm syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flail leg syndrome (see
         <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">
          "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Flail leg syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Other considerations in the differential diagnosis of MMN include the following [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic inflammatory demyelinating polyneuropathy (see
         <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">
          "Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multifocal acquired demyelinating sensory and motor neuropathy (see
         <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">
          "Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis", section on 'Asymmetric sensorimotor (multifocal)'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary neuropathy with liability to pressure palsy (see
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'Hereditary neuropathy with liability to pressure palsy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H126380009">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMN is treatable with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) [
         <a href="#rid12">
          12,14,25-29
         </a>
         ]. We suggest IVIG 2 g/kg, given over two to five days, for initial treatment of patients with MMN who require treatment due to disease progression or disability [
         <a href="#rid30">
          30
         </a>
         ]. Our preferred regimen is 0.4 g/kg daily for five consecutive days. This recommendation is consistent with current guidelines from the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) and the American Academy of Neurology [
         <a href="#rid24">
          24,28
         </a>
         ].
        </p>
        <p>
         The benefit of IVIG for MMN has been demonstrated in several small randomized controlled trials [
         <a href="#rid25">
          25-28,31
         </a>
         ]. As an example, a double-blind, placebo-controlled crossover trial evaluated IVIG (0.5 g/kg per day for five consecutive days once a month for three months) versus placebo in 18 patients with MMN [
         <a href="#rid25">
          25
         </a>
         ]. At four months, seven of nine patients who received IVIG responded, compared with two of nine patients treated with placebo. A 2022 systematic review of three placebo-controlled treatment trials in patients with MMN found that initial therapy with IVIG may improve muscle strength (78 versus 4 percent; risk ratio [RR] 11.0, 95% CI 2.9-42.3) and functional disability (39 versus 11 percent; RR 3.0, 95% CI 0.9-10.1) [
         <a href="#rid32">
          32
         </a>
         ]. However, the certainty of the evidence was low, owing to the small number of patients and variability in outcome measures used. Although data are less compelling, subcutaneous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (SCIG) therapy may also be beneficial for MMN, as reported in a meta-analysis that included mainly small observational studies [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Most patients experience a fairly rapid improvement in weakness with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . Muscles that show the greatest initial weakness have the largest response [
         <a href="#rid34">
          34
         </a>
         ]. However, the improvement is generally not sustained beyond a few months [
         <a href="#rid1">
          1
         </a>
         ]. In a trial of 44 patients with MMN treated with IVIG at baseline, worsening functional disability at 12 weeks was more common in patients receiving placebo than those receiving maintenance IVIG (40 versus 17 percent) [
         <a href="#rid35">
          35
         </a>
         ]. Therefore, maintenance IVIG infusions are typically required every two to six weeks. For patients who require maintenance IVIG infusions, subsequent dosing can be tailored to the individual patient based upon clinical response. Some patients will continue to require full-dose IVIG, while others will respond to lower doses. Maintenance IVIG is usually administered over a shorter time period if the initial five-day course is well tolerated. As an example, full-dose maintenance IVIG (total 2 g/kg) might be administered at 1 g/kg daily for two days.
        </p>
        <p>
         For patients with severe or progressive disease that is refractory to, or becomes resistant to,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         therapy, options and evidence are limited [
         <a href="#rid36">
          36
         </a>
         ]. Several reports suggest that
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         is partially effective for treating MMN [
         <a href="#rid5">
          5,37,38
         </a>
         ], but its use may be associated with serious toxicity. Responsiveness to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was reported in a few cases [
         <a href="#rid39">
          39,40
         </a>
         ], but rituximab was not associated with improvement on any outcome measures in a series of six patients with MMN [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         MMN is generally
         <strong>
          unresponsive
         </strong>
         to glucocorticoids or plasma exchange [
         <a href="#rid1">
          1
         </a>
         ], and these therapies have been associated with clinical worsening in some cases [
         <a href="#rid1">
          1,37,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H126380809">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of MMN is one of slow progression of disease and disability in untreated patients [
         <a href="#rid1">
          1,43
         </a>
         ]. Spontaneous remission has not been reported [
         <a href="#rid3">
          3
         </a>
         ]. In patients with very slow progression and minimal disability, immunomodulatory treatment may be deferred so as to avoid the risk of side effects. However, treatment should begin early in the disease if activities of living are impaired [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2131423527">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116787.html" rel="external">
          "Society guideline links: Neuropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126380796">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Multifocal motor neuropathy (MMN), also known as multifocal motor neuropathy with conduction block, is a rare neuropathy characterized by progressive, asymmetric weakness and atrophy without sensory abnormalities. It is considered an immune-mediated disorder that generally responds to treatment with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The typical clinical presentation of MMN is subacute onset of asymmetric weakness and lower motor neuron signs producing arm and hand weakness without associated sensory loss. The neuronal involvement in MMN is typically patchy, with some nerves unaffected and others severely involved. Motor nerve conduction studies usually show evidence of conduction block. Sensory conduction through the same segment of nerve is normal. Elevated titers of anti-GM1 antibodies are present in 30 to 80 percent of patients. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of MMN is suspected by a compatible clinical presentation of progressive, usually asymmetric weakness without sensory abnormalities, upper motor neuron signs, or bulbar involvement. The diagnosis is supported by nerve conduction studies that demonstrate focal demyelination and conduction block. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The main consideration in the differential diagnosis of MMN is amyotrophic lateral sclerosis/motor neuron disease. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – For patients with MMN who require treatment due to disease progression or disability, we suggest
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         2 g/kg, given over two to five days (eg, 0.4 g/kg daily for five consecutive days), as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Maintenance IVIG infusions are typically required every two to six weeks. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of MMN is one of slow progression of disease and disability in untreated patients. Most patients experience a fairly rapid initial improvement in weakness with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , but the improvement is generally not sustained beyond a few months. Maintenance treatment is typically required to slow disease progression. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           So YT. Immune-mediated neuropathies. Continuum (Minneap Minn) 2012; 18:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange DJ, Trojaborg W. Do GM1 antibodies induce demyelination? Muscle Nerve 1994; 17:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muley SA, Parry GJ. Multifocal motor neuropathy. J Clin Neurosci 2012; 19:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowacek DG, Teener JW. Multifocal motor neuropathy. Semin Neurol 2012; 32:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornberg AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve 1994; 17:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pestronk A. Invited review: motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle Nerve 1991; 14:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fionda L, Vanoli F, Di Pasquale A, et al. Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis. J Neurol 2018; 265:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenna MC, Marnane M, Sheane BJ, Connolly S. A case of multifocal motor neuropathy after initiation of ixekizumab for psoriatic arthopathy. Rheumatology (Oxford) 2021; 60:e282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor BV, Dyck PJ, Engelstad J, et al. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004; 63:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry 2015; 86:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishigaki H, Hiraide T, Miyagi Y, et al. Childhood-Onset Multifocal Motor Neuropathy With Immunoglobulin M Antibodies to Gangliosides GM1 and GM2: A Case Report and Review of the Literature. Pediatr Neurol 2016; 62:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007; 69:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 2010; 63:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pakiam AS, Parry GJ. Multifocal motor neuropathy without overt conduction block. Muscle Nerve 1998; 21:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz JS, Barohn RJ, Kojan S, et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology 2002; 58:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmont E, Azulay JP, Giorgi R, et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 2006; 67:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange DJ, Nijjar R, Voustianiouk A, et al. Do A-waves help predict intravenous immunoglobulin response in multifocal motor neuropathy without block? Muscle Nerve 2011; 43:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riva N, Iannaccone S, Corbo M, et al. Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann Neurol 2011; 69:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreisek G. Can MR Neurography Differentiate between Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy? Radiology 2019; 292:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronlage M, Knop KC, Schwarz D, et al. Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography. Radiology 2019; 292:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nobile-Orazio E, Cappellari A, Meucci N, et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002; 72:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst 2010; 15:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Léger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nobile-Orazio E, Gallia F. Multifocal motor neuropathy: current therapies and novel strategies. Drugs 2013; 73:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herraets I, van Rosmalen M, Bos J, et al. Clinical outcomes in multifocal motor neuropathy: A combined cross-sectional and follow-up study. Neurology 2020; 95:e1979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994; 44:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keddie S, Eftimov F, van den Berg LH, et al. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2022; 1:CD004429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis. Muscle Nerve 2017; 55:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakers JNE, van Eijk RPA, van den Berg LH, et al. Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy. Muscle Nerve 2021; 63:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn AF, Beydoun SR, Lawson V, et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 2013; 18:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2015; :CD003217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman EL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991; 30:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brannagan TH 3rd, Alaedini A, Gladstone DE. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006; 34:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004; 63:2178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stieglbauer K, Topakian R, Hinterberger G, Aichner FT. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 2009; 19:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst 2010; 15:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpo M, Cappellari A, Mora G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998; 50:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange DJ, Weimer LH, Trojaborg W, et al. Multifocal motor neuropathy with conduction block: slow but not benign. Arch Neurol 2006; 63:1778.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 89904 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22810071" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Immune-mediated neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264688" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Do GM1 antibodies induce demyelination?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22743043" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677657" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2843079" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264687" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The clinical and diagnostic role of anti-GM1 antibody testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1658646" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Invited review: motor neuropathies, motor neuron disorders, and antiglycolipid antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29767352" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33629111" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A case of multifocal motor neuropathy after initiation of ixekizumab for psoriatic arthopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14989599" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Multifocal motor neuropathy: pathologic alterations at the site of conduction block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25699569" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Nodopathies of the peripheral nerve: an emerging concept.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805527" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400822" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Childhood-Onset Multifocal Motor Neuropathy With Immunoglobulin M Antibodies to Gangliosides GM1 and GM2: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17954783" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20150737" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9466602" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Multifocal motor neuropathy without overt conduction block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865141" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Axonal multifocal motor neuropathy without conduction block or other features of demyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16924010" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Multifocal motor neuropathy with and without conduction block: a single entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21305570" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Do A-waves help predict intravenous immunoglobulin response in multifocal motor neuropathy without block?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21280090" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Motor nerve biopsy: clinical usefulness and histopathological criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31066626" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Can MR Neurography Differentiate between Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31063079" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12023421" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199100" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11133794" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7673950" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11087764" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454268" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23516024" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Multifocal motor neuropathy: current therapies and novel strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732293" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical outcomes in multifocal motor neuropathy: A combined cross-sectional and follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8145910" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35015296" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Immunoglobulin for multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27649063" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33501670" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24725024" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25739040" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1952828" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Immunosuppressive treatment in multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16502421" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596777" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467601" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Beneficial effect of rituximab monotherapy in multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040141" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9596014" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Deterioration of multifocal motor neuropathy after plasma exchange.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172619" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Multifocal motor neuropathy with conduction block: slow but not benign.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
